{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-009118","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2022-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.771460+00:00","generated_at":"2026-06-26T23:31:01.717589+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rocket Pharmaceuticals CFO resigns; appoints interim CFO and new director","bullets":["Fady Malik appointed to Board effective Mar 10; granted options for 33,199 shares (3-yr vest) and 8,641 shares (1-yr vest).","CFO Carlos Garcia-Parada resigns effective Mar 16 due to personal reasons; will advise through Mar 31.","John Militello, VP Finance and Controller, appointed interim Principal Financial Officer as of Mar 16.","Dr. Malik is EVP R&D at Cytokinetics, cardiologist, clinical professor at UCSF."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-009118","json":"https://secwatch.observer/filing/0001140361-22-009118.json","markdown":"https://secwatch.observer/filing/0001140361-22-009118.md","text":"https://secwatch.observer/filing/0001140361-22-009118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/0001140361-22-009118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/brhc10035116_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:31:01.717589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23adc17f58","claim":"Fady Malik was appointed as Director at ROCKET PHARMACEUTICALS, INC..","evidence_excerpt":"appointed Fady Malik, M.D., Ph.D., to the Board, effective March 10, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/0001140361-22-009118-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4e812a8976","claim":"Carlos Garcia-Parada resigned as Chief Financial Officer and Principal Financial Officer at ROCKET PHARMACEUTICALS, INC..","evidence_excerpt":"Carlos Garcia-Parada tendered his resignation as Chief Financial Officer and Principal Financial Officer of the Company, effective March 16, 2022, due to personal reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/0001140361-22-009118-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer and Principal Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"70787fb24d","claim":"John Militello was appointed as Interim Principal Financial Officer at ROCKET PHARMACEUTICALS, INC..","evidence_excerpt":"John Militello, the Company’s Vice President – Finance, Senior Controller, Treasurer and Principal Accounting Officer, was appointed as the interim Principal Financial Officer of the Company, as of the effective date of Mr. Garcia-Parada’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/0001140361-22-009118-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Principal Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}